Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
about
Latent reservoirs of HIV: obstacles to the eradication of virusEpstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infectionLaureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation.Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy.Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2.Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents.Ontogeny and expansion of human natural killer cells: clinical implications.Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responsesPathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2The use of interleukin-2 in human immunodeficiency virus infection.Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cellsInterleukin-2 Therapy Induces CD4 Downregulation, Which Decreases Circulating CD4 T Cell Counts, in African Green Monkeys.Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides.Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjectsIncreased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog.Multifarious immunotherapeutic approaches to cure HIV-1 infectionIn vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis.Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare.Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes.Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients.Treatment of idiopathic CD4 T lymphocytopenia with IL-2.Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment.Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.Identification of a novel G245R polymorphism in the IL-2 receptor beta membrane proximal domain associated with human visceral leishmaniasis.Cytokines and chemokines in HIV infection: implications for therapy.Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group.Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaquesOscillatory IL-2 stimulus reveals pertinent signaling timescales of T cell responsiveness
P2860
Q24615570-AFEB8A9F-EDE6-46A6-9193-6CFDC74340FCQ27022706-23C3E567-EEB0-4023-8AFD-7E48323CDC8EQ33717470-B86CFB18-F8BE-449A-8D95-C02B77F58ACFQ33772422-18523D4F-425C-40EF-8025-BC35E59A550AQ34067437-9E45E094-737D-4FCB-AF96-6706411F4399Q34169269-D94B5DC3-0CEC-4E8D-8F68-B4FDD5F88E65Q34255648-91480D3F-53E5-4C05-8E38-D877C8D3B7E7Q34257060-AB292376-5CC7-445F-B56F-8F98B1AFF6EBQ34511936-1C837FE6-16A9-4C78-8981-7F9E2B5E2711Q34552167-C2D8322A-C275-4DC7-83B0-95FE1B901426Q34633434-381A71AF-EE46-4B0A-9306-40A729CC6F35Q34650866-06158F9A-1AFA-408D-A59D-749A16A21C6CQ35826378-5482EB63-A82D-4B1D-B771-FB41C0F68E83Q35862206-6E91CFBF-92A4-448A-9588-601F586AF61CQ36047257-DF083114-2C51-4855-8EB3-F48D0F15F343Q36070906-37C055EE-79CA-440F-A6A7-3D6B7AA1E67CQ36352105-ED6C8B13-200F-4A2B-9FA8-ED59DA7087CCQ36890941-6248E4FD-B5D5-401D-97E0-F365CE35B5ECQ36950912-EA8393EA-78A7-4063-8B19-0A83943B8B41Q37379576-22C02E0E-EACC-4E81-B7FE-88CFF24042B7Q39287711-344A23C7-0FAE-4A55-B029-395732CDFB3FQ39630893-E4220D08-F08E-4318-8E2F-59755C27F065Q39794747-8FF23E74-DA58-4914-97F2-A05C1B5F1607Q40897178-E53ED447-EA6E-46BA-8C00-E596D84274A3Q41181556-961372E5-157D-4377-A844-6654E5FF22F1Q42007018-2305AE08-B8D3-415E-813B-0835B944D6C9Q42058939-69EDB29A-B804-4A8C-8BE1-A1862D2742DBQ42170591-193B287E-3241-4B16-A9A2-87419799C001Q44540464-D3BCA9BF-76E0-4524-B2E1-246CC0A915A9Q44571925-D9776D38-870F-4B28-ACCB-270BC3CCF107Q44593595-3E955F77-B4D7-4CCF-A578-C1ABFB59749EQ45376634-64425CA5-AF31-41D5-B7F3-06705C8AFDB6Q45753503-233C9D33-699A-4480-9F51-7F31D2323EBFQ46824244-6D48C6E4-E79A-4B36-8242-5A68322FE313Q47912506-940EDDC1-CEF3-4FBF-B180-21B2BC4C93DEQ52027267-21762F94-3CD5-49B1-AB70-E02FE4B28B4DQ57089576-4F325784-3926-4010-A432-3F55035FBFC3Q58727215-9E191195-8CD1-497D-A73C-42769D750C77
P2860
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rational interleukin 2 therapy ...... une function without toxicity.
@en
Rational interleukin 2 therapy ...... une function without toxicity.
@nl
type
label
Rational interleukin 2 therapy ...... une function without toxicity.
@en
Rational interleukin 2 therapy ...... une function without toxicity.
@nl
prefLabel
Rational interleukin 2 therapy ...... une function without toxicity.
@en
Rational interleukin 2 therapy ...... une function without toxicity.
@nl
P2093
P2860
P356
P1476
Rational interleukin 2 therapy ...... une function without toxicity.
@en
P2093
P2860
P304
10405-10410
P356
10.1073/PNAS.93.19.10405
P407
P577
1996-09-01T00:00:00Z